Everett, WANCT07767903Now EnrollingIRB Ready

Generalized Anxiety Disorder Clinical Trial in Everett, WA

Access cutting-edge generalized anxiety disorder treatment through this phase 3 clinical trial at a research site in Everett. Study-provided care at no cost to qualified participants.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.

Quick Self-Assessment

See if you qualify for this Everett location

Preparing your pre-screening questions…

Expert Care in Everett

Access generalized anxiety disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related generalized anxiety disorder treatment provided free

Apply for This Everett Location

Check if you qualify for this generalized anxiety disorder clinical trial in Everett, WA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Everett

    Convenient for WA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Everett site if eligible
  4. 4Begin participation

About This Generalized Anxiety Disorder Study in Everett

This is a global, phase 3, randomized, double-blind, parallel-group, 2-arm, placebo controlled, multicenter trial designed to compare the efficacy, safety and tolerability of a fixed dose of SEP-363856 (75 millligrams per day \[mg/day\]) to placebo over an 8-week double-blind treatment period in adults with generalized anxiety disorder (GAD).

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Who Can Participate

Inclusion Criteria

Male or female participants at least 18 years of age at the time of informed consent
Primary diagnosis of GAD per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by Mini-International Neuropsychiatric Interview (MINI) and clinical psychiatric evaluation
Body Mass Index (BMI) 18-40 kilograms per square meter (kg/m\^2)
Participant is willing and able to comply with study procedures and visit schedule
Medically stable as determined by medical history, physical exam, vital signs, and laboratory tests and able to comply with study procedures
Willing and able to discontinue prohibited medications/therapies per protocol
(i ) Females of childbearing potential: negative pregnancy test and agreement to use acceptable contraception (ii) Males: agreement to follow protocol-defined contraception and reproductive restrictions
Willing and able to discontinue prohibited medications/therapies per protocol Key

Exclusion Criteria

Current DSM-5 diagnosis of major depressive episode, post traumatic stress disorder (PTSD), or any psychiatric disorder other than GAD that was the primary focus of treatment within 12 months prior to screening
Substance use disorder (excluding nicotine/caffeine) within 12 months prior to screening
Lifetime history of certain psychiatric disorders (e.g., schizophrenia spectrum disorders, bipolar disorder, obsessive-compulsive disorder, borderline or antisocial personality disorder)
Significant suicide risk e.g., recent suicidal behavior/ideation per Columbia-Suicide Severity Rating Scale \[C-SSRS\] or MADRS)
Use of prohibited medications/therapies within protocol-defined timeframes (e.g., certain antipsychotics, mood stabilizers, benzodiazepines, investigational treatments)
Prior exposure to restricted treatments
Pregnant or breastfeeding females
Participation in another investigational study within 180 days (or more than \[\>\] 1 trial in last year)
Known history of human immunodeficiency virus seropositivity, hepatitis B or C

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Everett?

Yes, this clinical trial (NCT07767903) has an active research site in Everett, WA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Generalized Anxiety Disorder Treatment Options in Everett, WA

If you're searching for generalized anxiety disorder treatment options in Everett, WA, this clinical trial (NCT07767903) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Everett research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced generalized anxiety disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all generalized anxiety disorder clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Everett, WA

See all essential tremor clinical trials recruiting in Everett — not just this study.

Browse Essential Tremor Trials in Everett →

Ready to Join in Everett?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Everett, WA